Astellas profits up despite Lipitor's Japanese slump and Tarceva HCC failure
This article was originally published in Scrip
Executive Summary
Astellas has confirmed as expected that it has now dropped Tarceva (erlotinib) for unresectable hepatocellular carcinoma (HCC) following the recent Phase III failure of the multiple kinase inhibitor in this indication.